Nabriva Therapeutics plc (NBRVF)

OTCMKTS: NBRVF · Delayed Price · USD
0.0001
0.00 (0.00%)
Apr 17, 2024, 1:24 PM EDT - Market open
Market Cap 323.00
Revenue (ttm) 29.56M
Net Income (ttm) -55.05M
Shares Out 3.23M
EPS (ttm) -1.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10
Open 0.0001
Previous Close 0.0001
Day's Range 0.0001 - 0.0001
52-Week Range n/a
Beta 1.64
Analysts n/a
Price Target n/a
Earnings Date n/a

About NBRVF

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infect... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Sep 18, 2015
Employees 39
Stock Exchange OTCMKTS
Ticker Symbol NBRVF
Full Company Profile

Financial Performance

In 2022, NBRVF's revenue was $36.94 million, an increase of 27.82% compared to the previous year's $28.90 million. Losses were -$57.19 million, 15.6% more than in 2021.

Financial Statements

News

Nabriva Therapeutics Provides Corporate Update

-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations-

1 year ago - GlobeNewsWire

Nabriva's stock is up after sharing antibiotic news

Shares of Nabriva Therapeutics Plc NBRV, were up 13.8% in premarket trading on Monday after the company said in a news release it had positive data from a Phase 1 clinical trial assessing its antibiot...

1 year ago - Market Watch

Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

- PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects –

1 year ago - GlobeNewsWire

Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update

- Shifted Focus to SIVEXTRO to Enable Cost Cutting -

1 year ago - GlobeNewsWire

Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn...

1 year ago - GlobeNewsWire

Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 15, 2022 (GLOBE NEWSWIRE) --  Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of i...

1 year ago - GlobeNewsWire

Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of in...

1 year ago - GlobeNewsWire

Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

- Topline Data Expected First Quarter 2023 - - Topline Data Expected First Quarter 2023 -

1 year ago - GlobeNewsWire

Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

-Net Product Sales of $8.7M Grew 25% versus Q2 2021-

1 year ago - GlobeNewsWire

Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022

DUBLIN, Ireland and FORT WASHINGTON, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn...

1 year ago - GlobeNewsWire

Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticals

DUBLIN, Ireland and FORT WASHINGTON, Pa., July 18, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn...

1 year ago - GlobeNewsWire

Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment Conference

DUBLIN, Ireland, May 13, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective age...

2 years ago - GlobeNewsWire

Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

-SIVEXTRO Distribution and Promotion Agreement with Merck Formally Extended Through at Least 2026-

2 years ago - GlobeNewsWire

Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026

DUBLIN, Ireland and FORT WASHINGTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) --  Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn...

2 years ago - GlobeNewsWire

Nabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022

DUBLIN, Ireland and FORT WASHINGTON, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inno...

2 years ago - GlobeNewsWire

Nabriva Therapeutics Announces First Patient Enrolled in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

DUBLIN, Ireland and FORT WASHINGTON, Pa., April 11, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of in...

2 years ago - GlobeNewsWire

Nabriva Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

-Total revenue of $9.3 million driven by continued SIVEXTRO prescription growth-

2 years ago - GlobeNewsWire

Nabriva Therapeutics to Report 2021 Financial Results and Recent Corporate Highlights on March 29, 2022

DUBLIN, Ireland and FORT WASHINGTON, Pa., March 15, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of in...

2 years ago - GlobeNewsWire

Nabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, Ireland, March 01, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective a...

2 years ago - GlobeNewsWire

Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders on January 18, 2022

— Meeting to Reconvene on March 24, 2022 —

2 years ago - GlobeNewsWire

Nabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders

— Meeting to Reconvene on January 18, 2022 —

2 years ago - GlobeNewsWire

Nabriva Therapeutics Provides Business Update and Announces Preliminary Financial Results for the Fourth Quarter of 2021

-SIVEXTRO ® (tedizolid phosphate) remains on track for return to historical peak sales by mid-2022-

2 years ago - GlobeNewsWire

Nabriva Therapeutics to Adjourn Extraordinary General Meeting of Shareholders on December 22, 2021

— Meeting to Reconvene on January 14, 2022 — — Meeting to Reconvene on January 14, 2022 —

2 years ago - GlobeNewsWire

Nabriva Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

DUBLIN, Ireland and FORT WASHINGTON, Pa., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn...

2 years ago - GlobeNewsWire

Lefamulin NDA Filed in Mainland China for Treatment of Community Acquired Pneumonia

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn...

2 years ago - GlobeNewsWire